Cytokinetics Yönetim
Yönetim kriter kontrolleri 4/4
Cytokinetics CEO'su Robert Blum, Feb2006 tarihinde atandı, in görev süresi 20.33 yıldır. in toplam yıllık tazminatı $ 11.88M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.2% maaş ve 92.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.18% ine doğrudan sahiptir ve bu hisseler $ 18.73M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.1 yıl ve 13.3 yıldır.
Anahtar bilgiler
Robert Blum
İcra Kurulu Başkanı
US$11.9m
Toplam tazminat
| CEO maaş yüzdesi | 7.18% |
| CEO görev süresi | 20.3yrs |
| CEO sahipliği | 0.2% |
| Yönetim ortalama görev süresi | 5.1yrs |
| Yönetim Kurulu ortalama görev süresi | 13.3yrs |
Son yönetim güncellemeleri
Recent updates
Analiz Makalesi • 13h
Cytokinetics (CYTK) Stock Could Be 15% Undervalued After Myqorzo Approval
Cytokinetics (CYTK) is back in focus after the FDA cleared its first commercial product, Myqorzo, for symptomatic obstructive hypertrophic cardiomyopathy, with early launch data and European approvals drawing fresh attention to the stock. See our latest analysis for Cytokinetics. Against this backdrop, Cytokinetics' short term share price momentum has been strong, with a 7 day share price return of 13.73% and a 90 day share price return of 27.68%. Its 1 year total shareholder return of...
Anlatı Güncellemesi • Jun 16
CYTK: HCM Launch And ACACIA Phase 3 Readout Will Drive Repricing
The analyst price target for Cytokinetics has been revised higher by $5 to $99, with analysts pointing to optimism around the Myqorzo launch in obstructive hypertrophic cardiomyopathy and underappreciated potential in nonobstructive disease, supported by expectations around fuller Phase 3 ACACIA-HCM data. Analyst Commentary Recent research on Cytokinetics highlights a cluster of bullish analysts who are focused on execution around the Myqorzo launch, the potential in nonobstructive hypertrophic cardiomyopathy, and upcoming clinical data from the ACACIA-HCM program.Anlatı Güncellemesi • Jun 02
CYTK: Positive HCM Data And Launch Execution Will Drive 2026 Repricing Potential
Analysts have nudged Cytokinetics' fair value estimate higher from about $123.09 to $136.89, citing increased confidence in the Myqorzo launch in obstructive hypertrophic cardiomyopathy, as well as potential upside from nonobstructive disease, as key drivers behind recent price target increases and new coverage initiations. Analyst Commentary Recent Street research around Cytokinetics centers on expectations for the Myqorzo launch in obstructive hypertrophic cardiomyopathy and the potential extension into nonobstructive disease.Analiz Makalesi • May 17
Need To Know: Analysts Are Much More Bullish On Cytokinetics, Incorporated (NASDAQ:CYTK) Revenues
Shareholders in Cytokinetics, Incorporated ( NASDAQ:CYTK ) may be thrilled to learn that the analysts have just...
Anlatı Güncellemesi • May 14
CYTK: Future Returns Will Depend On HCM Launch And ACACIA Readout
Analysts have raised their average price target for Cytokinetics by about $5, citing a mix of updated trial expectations, improved projected profit margins, and adjustments to long term valuation assumptions. Analyst Commentary Recent research updates highlight a generally constructive stance on Cytokinetics, with several large firms lifting their price targets following product approval milestones, early launch indicators for Myqorzo in obstructive hypertrophic cardiomyopathy, and upcoming Phase 3 readouts in non obstructive disease.Seeking Alpha • May 10
Cytokinetics: Aficamten Has Momentum, But The Stock Is Too Expensive (Rating Downgrade)
Summary CYTK has begun its US launch of Myqorzo. So far, its early prescribing demand seems promising, and they’re moving towards its full commercial ramp. Additionally, aficamten recently met both primary endpoints in Phase 3 ACACIA-HCM for non-obstructive HCM. Similarly, CYTK’s MAPLE-HCM sNDA has been accepted, with a November 2026 PDUFA date. CYTK’s balance sheet also appears quite liquid today. After their recent equity offering, I estimate they now have a comfortable cash runway. Unfortunately, I feel CYTK’s valuation is now much more expensive than when I first covered it. So, ideally, I think you should wait for a dip before adding more shares. Read the full article on Seeking AlphaAnaliz Makalesi • May 07
Earnings Update: Cytokinetics, Incorporated (NASDAQ:CYTK) Just Reported And Analysts Are Boosting Their Estimates
The investors in Cytokinetics, Incorporated 's ( NASDAQ:CYTK ) will be rubbing their hands together with glee today...
Anlatı Güncellemesi • Apr 29
CYTK: ACACIA Trial Readout Will Drive Next Phase Of Momentum
The analyst price target for Cytokinetics has shifted higher to $92.94 from $79.56, with analysts pointing to stronger modeled revenue growth, a higher future P/E assumption tied to growing interest in Myqorzo and ACACIA trial catalysts, as well as updated discount rate and margin forecasts. Analyst Commentary Recent research updates cluster around the same core themes, with most activity tied to reactions to Myqorzo approval for obstructive hypertrophic cardiomyopathy, expectations for the ACACIA non obstructive HCM trial, and tweaks to long term loss and margin forecasts.Anlatı Güncellemesi • Apr 14
CYTK: Future Returns Will Hinge On HCM Launch And ACACIA Trial Outcome
The analyst price target for Cytokinetics is now set at $67.00. This level is supported by analysts highlighting early Myqorzo launch traction in obstructive hypertrophic cardiomyopathy, growing focus on upcoming non obstructive HCM data, and updated assumptions around expenses and interest income.Anlatı Güncellemesi • Mar 31
CYTK: Future Returns Will Depend On HCM Launch And ACACIA Outcome
Cytokinetics' fair value estimate has been revised to $67 from $61, reflecting analysts' higher price targets tied to early Myqorzo launch signals and the potential impact of upcoming ACACIA non obstructive HCM data. Analyst Commentary Recent Street research on Cytokinetics has centered on two main themes: Myqorzo's early launch trends in obstructive hypertrophic cardiomyopathy and the upcoming ACACIA readout in non obstructive HCM.Anlatı Güncellemesi • Mar 17
CYTK: Upcoming ACACIA nHCM Readout Will Drive 2026 Repricing Potential
Analysts have raised their average price targets for Cytokinetics, citing updated views on the ACACIA nHCM trial, early MYQORZO launch progress, and revised loss and expense assumptions. Together, these factors support a slightly higher fair value estimate of about $123 per share.Anlatı Güncellemesi • Mar 03
CYTK: Future Returns Will Depend On HCM Data And Launch Execution
Analysts have lifted their average price targets on Cytokinetics by several dollars into a $67 to $101 range, citing Q4 updates, early MYQORZO launch traction in obstructive hypertrophic cardiomyopathy, and expectations around upcoming ACACIA trial data in both obstructive and non obstructive HCM. Analyst Commentary Across recent research updates, analysts have been adjusting their models and views on Cytokinetics around Q4 results, the early MYQORZO launch in obstructive hypertrophic cardiomyopathy, and expectations for the ACACIA program in both obstructive and non obstructive HCM.Anlatı Güncellemesi • Feb 17
CYTK: Fair Value Reset Will Hinge On Execution Of Commercial Transition
The analyst fair value estimate for Cytokinetics has moved to $61 from $55. This change reflects updated views from recent Street research that highlight revised revenue growth, profit margin, and P/E assumptions following a series of price target increases across several firms.Anlatı Güncellemesi • Feb 03
CYTK: 2026 HCM Launch And Cost Discipline Will Shape Repricing Potential
Analysts have nudged their fair value target for Cytokinetics higher from about US$120 to roughly US$122 per share, reflecting updated revenue, margin and P/E assumptions following a series of recent price target increases and Overweight or Outperform views across several firms. Analyst Commentary Recent Street research has largely leaned constructive on Cytokinetics, with several bullish analysts revisiting their models and price targets around key pipeline and financial milestones.Analiz Makalesi • Jan 27
Need To Know: The Consensus Just Cut Its Cytokinetics, Incorporated (NASDAQ:CYTK) Estimates For 2026
Market forces rained on the parade of Cytokinetics, Incorporated ( NASDAQ:CYTK ) shareholders today, when the analysts...Anlatı Güncellemesi • Jan 19
CYTK: Anticipated 2026 HCM Launch Will Drive Repricing Potential
Narrative Update on Cytokinetics The analyst price target for Cytokinetics has been nudged higher in line with a modest fair value increase to about $120.25, as analysts factor in updated revenue and expense modeling around the potential 2026 launch of aficamten and continued interest in U.S. small to mid cap biotech names. Analyst Commentary Recent research updates around Cytokinetics center on recalibrated price targets and refreshed modeling for aficamten and operating expenses, as analysts refine their views ahead of a potential 2026 commercial launch.Anlatı Güncellemesi • Jan 05
CYTK: Aficamten Launch Path And Cash Outlook Will Drive Repricing
Analysts have lifted their price targets on Cytokinetics, with recent moves such as RBC's increase to US$87 and BofA's incremental raises to US$63. These changes reflect updated modeling on operating expenses, revenue assumptions around the anticipated 2026 aficamten launch, and revised net cash forecasts.Anlatı Güncellemesi • Dec 17
CYTK: Elevated Expectations For 2026 Launch Will Likely Prove Difficult To Sustain
The analyst price target for Cytokinetics has been raised from $41.00 to $55.00 as analysts factor in stronger aficamten launch expectations, higher long term revenue growth and margin assumptions, and updated operating expense forecasts informed by recent Street research. Analyst Commentary Recent Street research on Cytokinetics reflects a constructive but increasingly nuanced outlook as the aficamten launch approaches.Anlatı Güncellemesi • Dec 03
CYTK: Momentum Will Build Ahead Of Late Cycle FDA Decision
Analysts have nudged their blended price target for Cytokinetics modestly higher, with our fair value estimate increasing from about $78.44 to $79.56. Updated models reflect stronger long term aficamten launch dynamics, refined operating expense assumptions, and incremental confidence around regulatory and commercial execution.Anlatı Güncellemesi • Nov 19
CYTK: Momentum Will Build Ahead Of Anticipated FDA Decision Next Year
Analysts have modestly raised their price targets for Cytokinetics, with updated forecasts supported by expectations for robust aficamten launch dynamics, improved projected revenue growth, and refined operating expense assumptions. This has led to an increase in fair value from $76.67 to $78.44 per share.Anlatı Güncellemesi • Nov 05
CYTK: Strong Cardiology Data Will Drive Momentum Ahead Of December 2025 FDA Decision
Analysts have modestly raised their price target for Cytokinetics, increasing it by nearly $1 to approximately $76.67. They cite ongoing favorable feedback on aficamten from recent medical meetings and firm research updates.Anlatı Güncellemesi • Oct 22
Analyst Commentary Highlights Shifting Sentiment on Cytokinetics Amid Aficamten Progress and Valuation Changes
Analysts have raised their average price target for Cytokinetics by approximately $1.42 to $75.83. This reflects increased confidence in aficamten's upcoming launch and updated forecasts following positive regulatory and clinical developments.Anlatı Güncellemesi • Sep 18
Precision Medicine And Late-stage Trials Will Expand Global Reach
Cytokinetics’ consensus price target was modestly raised to $74.41, as strong MAPLE trial data for aficamten de-risked its profile, reinforced first-line oHCM potential, and highlighted underappreciated pipeline optionality, all outweighing near-term market adoption headwinds. Analyst Commentary Bullish analysts highlighted strong MAPLE trial data for aficamten presented at ESC, reinforcing confidence in its clinical value and de-risked, best-in-disease positioning for oHCM.Anlatı Güncellemesi • Sep 03
Precision Medicine And Late-stage Trials Will Expand Global Reach
Upward revisions in analyst price targets for Cytokinetics reflect increased confidence in aficamten’s strong Phase 3 data, anticipated favorable FDA outcomes, and expanded commercial prospects, partially offset by concerns over possible REMS limitations and launch pacing, resulting in a higher consensus price target of $73.21. Analyst Commentary Bullish analysts highlight strong Phase 3 MAPLE-HCM and extension study data for aficamten, citing de-risked profile and high efficacy/safety, increasing their confidence ahead of regulatory decisions.Yeni Anlatı • Aug 10
Precision Medicine And Late-stage Trials Will Expand Global Reach
Successful late-stage clinical trials, commercial readiness, and diversification in products position the company for strong growth and reduced dependence on a single therapy.Seeking Alpha • Mar 16
Cytokinetics Nears Approval: 'Buy' The New Potential Cardiology Franchise With Aficamten
Summary Cytokinetics is now rapidly moving into commercialization efforts with Aficamten. If all goes well, it could be approved by September 2025. Aficamten had favorable Phase 3 data, so it could have solid competitive prospects if approved, possibly with better safety and simpler dosing. Although CYTK looks a bit pricey today, Aficamten’s $10 billion TAM by 2035 makes CYTK’s valuation much more reasonable. Still, regulatory and competitive risks remain, but I think CYTK’s rollout strategy and broader franchise ambitions outweigh the downside risks. Overall, I believe CYTK is a great long-term “Buy” due to Aficamten’s potential as an emerging blockbuster drug in cardiology. Read the full article on Seeking AlphaCEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$830m |
| Dec 31 2025 | US$12m | US$853k | -US$785m |
| Sep 30 2025 | n/a | n/a | -US$752m |
| Jun 30 2025 | n/a | n/a | -US$606m |
| Mar 31 2025 | n/a | n/a | -US$615m |
| Dec 31 2024 | US$14m | US$820k | -US$590m |
| Sep 30 2024 | n/a | n/a | -US$576m |
| Jun 30 2024 | n/a | n/a | -US$545m |
| Mar 31 2024 | n/a | n/a | -US$531m |
| Dec 31 2023 | US$9m | US$782k | -US$526m |
| Sep 30 2023 | n/a | n/a | -US$527m |
| Jun 30 2023 | n/a | n/a | -US$540m |
| Mar 31 2023 | n/a | n/a | -US$431m |
| Dec 31 2022 | US$9m | US$742k | -US$389m |
| Sep 30 2022 | n/a | n/a | -US$282m |
| Jun 30 2022 | n/a | n/a | -US$216m |
| Mar 31 2022 | n/a | n/a | -US$258m |
| Dec 31 2021 | US$6m | US$709k | -US$215m |
| Sep 30 2021 | n/a | n/a | -US$229m |
| Jun 30 2021 | n/a | n/a | -US$156m |
| Mar 31 2021 | n/a | n/a | -US$135m |
| Dec 31 2020 | US$5m | US$682k | -US$127m |
| Sep 30 2020 | n/a | n/a | -US$114m |
| Jun 30 2020 | n/a | n/a | -US$140m |
| Mar 31 2020 | n/a | n/a | -US$132m |
| Dec 31 2019 | US$3m | US$656k | -US$122m |
Tazminat ve Piyasa: Robert 'ın toplam tazminatı ($USD 11.88M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 14.67M ).
Tazminat ve Kazançlar: Robert 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Robert Blum (62 yo)
20.3yrs
Görev süresi
US$11,881,456
Tazminat
Mr. Robert I. Blum has been Chief Executive Officer, President and Director of Cytokinetics, Incorporated since January 22, 2007 and served as its Principal Financial Officer until May 08, 2024. Mr. Blum p...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, President & Director | 20.3yrs | US$11.88m | 0.18% $ 18.7m | |
| EVP & CFO | 2.1yrs | US$3.77m | 0.0016% $ 168.6k | |
| Executive VP | less than a year | US$6.09m | Veri yok | |
| Executive Vice President of Research & Development | 14yrs | US$4.47m | 0.073% $ 7.7m | |
| Executive VP & Chief Commercial Officer | 5.3yrs | US$3.79m | 0.0012% $ 124.1k | |
| Co-Founder & Chairman of Scientific Advisory Board | 28.8yrs | US$41.50k | Veri yok | |
| Co-Founder & Member of Scientific Advisory Board | 28.8yrs | US$21.94k | Veri yok | |
| Vice President of Sales & Operations | 4.8yrs | Veri yok | Veri yok | |
| VP of Accounting & Corporate Controller | 1.3yrs | Veri yok | Veri yok | |
| Senior Vice President of Global Supply Chain Operations & Technical Operations | no data | Veri yok | Veri yok | |
| Senior Vice President of Global Marketing & Commercial Strategy | 5.1yrs | Veri yok | Veri yok | |
| EVP of Corporate Development & Chief Business Officer | 2yrs | Veri yok | Veri yok |
5.1yrs
Ortalama Görev Süresi
62yo
Ortalama Yaş
Deneyimli Yönetim: CYTK 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.1 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, President & Director | 19.4yrs | US$11.88m | 0.18% $ 18.7m | |
| Co-Founder & Chairman of Scientific Advisory Board | 18.2yrs | US$41.50k | Veri yok | |
| Co-Founder & Member of Scientific Advisory Board | no data | US$21.94k | Veri yok | |
| Independent Director | 13.3yrs | US$540.00k | 0.012% $ 1.2m | |
| Independent Director | 5.6yrs | US$501.34k | 0.025% $ 2.6m | |
| Independent Chairman | 17.3yrs | US$480.29k | 0.058% $ 6.1m | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 9.9yrs | US$942.23k | Veri yok | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 5.3yrs | US$520.75k | 0.019% $ 2.1m |
13.3yrs
Ortalama Görev Süresi
70yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: CYTK 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 13.3 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/18 15:38 |
| Gün Sonu Hisse Fiyatı | 2026/06/18 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Cytokinetics, Incorporated 37 Bu analistlerden 19, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Carter Gould | Barclays |
| Emily Field | Barclays |
| Huidong Wang | Barclays |